<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03235752</url>
  </required_header>
  <id_info>
    <org_study_id>CTJ301UC201</org_study_id>
    <nct_id>NCT03235752</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis</brief_title>
  <official_title>A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leading Biopharm Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leading Biopharm Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled phase II study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      is a multicenter, randomized, double-blind, placebo-controlled phase II study. The trial
      includes a Run-in Period (if stable conventional treatment needed), a 4-week Screening
      Period, a 12-week Treatment Period, and a 3-week Safety Follow-up Period to Day 105.

      90 patients will be centrally, dynamically, randomly assigned to 3 groups (1:1:1) to receive
      600mg TJ301 biweekly (Q2W), 300mg TJ301 Q2W or placebo Q2W.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-blind, Placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomized, Double-blind, Placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and endoscopic remission at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical and endoscopic remission at Week 12, defined as a full Mayo score ≤2, no individual subscore &gt;1, rectal bleeding subscore = 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and endoscopic response</measure>
    <time_frame>Week 12.</time_frame>
    <description>Clinical and endoscopic response (decrease from Baseline in full Mayo score ≥3 and ≥30%, including decrease from Baseline in rectal bleeding subscore ≥1 or rectal bleeding subscore ≤1) at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission at Weeks 4, 6, 8, 10, and 12</measure>
    <time_frame>Weeks 4, 6, 8, 10, and 12</time_frame>
    <description>Clinical remission at Weeks 4, 6, 8, 10, and 12 defined as a stool frequency subscore=0, rectal bleeding subscore = 0, and 9-point partial Mayo score ≤1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline to Weeks 4, 8, and 12 in exploratory biomarkers</measure>
    <time_frame>Baseline to Weeks 4, 8, and 12</time_frame>
    <description>Change from Baseline to Weeks 4, 8, and 12 in exploratory biomarkers (erythrocyte sedimentation rate [ESR], C-reactive protein (CRP), IL-6, IL-6/sIL-6R complex, neutrophil and platelet count, faecal calprotectin).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Active Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>TJ301 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TJ301 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administrations will occur on Days 0, 14, 28, 42, 56, and 70.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ301 300mg</intervention_name>
    <description>TJ301 300mg IV infusion</description>
    <arm_group_label>TJ301 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ301 600mg</intervention_name>
    <description>TJ301 600mg IV infusion</description>
    <arm_group_label>TJ301 600mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients 18-70 (inclusive) years of age.

          2. History of active UC of more than 3 months. Active UC confirmed by colonoscopy with
             biopsy or flexible sigmoidoscopy with biopsy at Screening, with extending &gt; 15-cm past
             the anal verge from endoscopy. Biopsy sample is not necessary if UC is already
             confirmed.

          3. Active UC with a full Mayo score≥5 and a rectal bleeding subscore ≥1 at screening.

          4. During Day -35 to Day -6 prior to Randomisation, an endoscopy subscore ≥2.

          5. Treated with conventional non-biological UC therapy: with corticosteroids stable for
             at least 2 weeks prior to Randomization at no more than 20 mg prednisone per day (or
             equivalent), and/or with medications containing 5-aminosalicylates (5-ASA) at no less
             than 2 g 5-ASA per day for at least 3 months and stable for at least 4 weeks prior to
             Randomization, and/or with azathioprine (AZA) at no less than 0.75 mg/kg/day or
             mercaptopurine (6-MP) at no less than 0.5 mg/kg/day for at least 6 months and stable
             for at least 6 weeks prior to Randomization, or MTX no less than 12.5 mg/week and
             stable for at least 12 weeks prior to Randomization.

        Exclusion Criteria:

          1. Pregnant or breastfeeding women.

          2. Contraindication to colonoscopy or sigmoidoscopy.

          3. Allergies to any component of TJ301.

          4. History of colostomy, colectomy or partial colectomy.

          5. Current diagnosis of inflammatory bowel disease unclassified, Crohn's disease,
             ischemic colitis, fulminant colitis and/or toxic megacolon, patients with ulcerative
             colitis limited to the rectum (ulcerative proctitis), infective enteritis, amebic
             bowel disease and intestinal schistosomiasis.

          6. History of malignancy other than a successfully treated non-metastatic cutaneous
             squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the
             cervix. If the Screening colonoscopy shows evidence of dysplasia or a malignancy, the
             patient is not eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Hu Cheng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yin Liu, Master</last_name>
    <phone>+8613501781723</phone>
    <email>yin.liu@i-mabbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Linear clinical Research</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Callum ierce</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>1st affiliated hospital Sun Yat-sen University</name>
      <address>
        <city>Guanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minhuo Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>bo-lin lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Tang Chiu, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Jium Shieh, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2017</study_first_submitted>
  <study_first_submitted_qc>July 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2017</study_first_posted>
  <last_update_submitted>December 29, 2017</last_update_submitted>
  <last_update_submitted_qc>December 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized</keyword>
  <keyword>Double-blind</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Active Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

